ERLEADA® Outperforms Enzalutamide in Study

Johnson & Johnson (NYSE: JNJ) has announced significant findings from a landmark real-world, head-to-head study, revealing that ERLEADA® (apalutamide) offers a statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide for patients with metastatic castration-sensitive prostate cancer (mCSPC). The results were presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon, Portugal, on October 2, 2024 (Abstract #P31).

Key Findings of the Study

The study, which involved nearly 4,000 patients, represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in the mCSPC patient population. It demonstrated that ERLEADA® reduced the risk of death by 23 percent at 24 months compared to enzalutamide. According to the study, patients who initiated treatment with ERLEADA® as their first ARPI had a hazard ratio (HR) of 0.77 (95% confidence interval [CI], 0.62-0.96; P<0.019) in relation to their risk of death at the 24-month mark.

The proportion of patients alive at 24 months in the ERLEADA® cohort was 87.6 percent, aligning closely with the Phase 3 TITAN trial, which reported an 82.4 percent survival rate. The TITAN trial demonstrated a statistically significant overall survival benefit of ERLEADA® in conjunction with androgen deprivation therapy (ADT) compared to ADT alone, with HRs of 0.67 (95% CI, 0.51-0.89; P=0.005) at the primary analysis and 0.65 (95% CI, 0.53-0.79; P<0.0001) at the final analysis.

Expert Insights

Dr. Neal Shore, F.A.C.S., Steering Committee Chair and Medical Director at Carolina Urologic Research Center, stated, “This real-world evidence showed a statistically significant and clinically meaningful improvement in survival with apalutamide over enzalutamide in patients with mCSPC at 24 months.” He emphasized the value of the comprehensive data and rigorous methodology employed in this study, which offers essential insights for prescribers choosing an ARPI.

Dr. Luca Dezzani, M.D., U.S. Vice President of Medical Affairs for Solid Tumors at Johnson & Johnson Innovative Medicine, noted, “ERLEADA is the only ARPI to demonstrate a survival benefit as early as 22 months, as seen in the TITAN study. While many ARPIs have emerged since ERLEADA’s approval, this study represents the first large-scale comparison of their effectiveness.” He underscored ERLEADA's patient-centric design, requiring just one daily pill.

Study Limitations

Despite its significant findings, the study acknowledges potential limitations, including possible miscoding or missing data within the sources. However, the methodologies used were determined to be suitable for accurately identifying the patient population and assessing survival outcomes. While the current analysis focused on 24-month survival rates, further long-term studies are essential to comprehensively evaluate the therapeutic effects of these treatments.

Highlights

• ERLEADA® shows a 23% reduction in the risk of death compared to enzalutamide at 24 months.
• Study includes nearly 4,000 patients, the largest real-world analysis in the mCSPC category.
• Survival rates for ERLEADA® are consistent with previous Phase 3 TITAN trial results.
• Experts emphasize the study's rigorous methodology and real-world applicability.
• Further long-term studies are required to fully evaluate treatment effects.